Clinical trial · Interventional
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
NCT00539253CI-TRIAL-00029661TACEcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gadobenate dimeglumine (MultiHance) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Gadobenate Dimeglumine (Multi Hance)
- description
- If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
- interventionNames
- Drug: gadobenate dimeglumine (MultiHance)
Primary outcomes (2)
- measure
- Nodule Size
- timeFrame
- 3 months
- description
- Maximal nodule size measured in centimeters
- measure
- Nodule Enhancement
- timeFrame
- 3 month
- description
- Percent area of nodule with enhancement
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE. * International Normalized Ratio (INR) \<1.4 * Platelet count \> 80,000 Exclusion Criteria: * Contraindications to TACE procedure * Unable to have an MRI Scan * Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol * Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias * Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders * Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate\<15cc/min) * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.